Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

This Phase 1 study tests a combination of two immunotherapy/targeted therapy drugs — lenvatinib and pembrolizumab — together with focused pelvic radiation for women with endometrial (uterine) cancer that has come back or cannot be surgically removed. The cancer must be of a type that lacks certain DNA repair proteins (called pMMR), which typically responds less well to standard immunotherapy alone. **You may be eligible if...** - You have recurrent or unresectable endometrial cancer confirmed by biopsy - Your cancer is pMMR (a specific molecular type determined by testing) - You have already had surgery, or your cancer cannot be surgically removed - Radiation therapy has been determined to be appropriate for your situation - Your general health and organ function meet required levels **You may NOT be eligible if...** - Your cancer is the dMMR/MSI-high type (a different molecular subtype) - You have had prior pelvic radiation that overlaps with the planned treatment area - You have autoimmune conditions or are on immunosuppressive treatment - You are pregnant Talk to your doctor to see if this trial is right for you.